4-(3-Bromophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1h)-one | 191219-81-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-(3-Bromophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1h)-one
• 英文别名: 4-(3-bromophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2-one
• CAS: 191219-81-5
• 化学式: C₁₇H₁₆BrN₃O
• 分子量: 358.2
• InChiKey: YAAACGHPCYZCKO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  45.6
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF
  申请人：YAMANOUCHI PHARMACEUTICAL CO., LTD.

  公开号：EP0885894A1

  公开（公告）日：1998-12-23

  Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof which have the effect of inhibiting the activity of type IV phosphodiesterases and are usable as drugs, in particular, type IV phosphodiesterase inhibitors or preventives and remedies for diseases in association with the sthenic type IV phosphodiesterase activity, in particular, respiratory diseases such as bronchial asthma. In said formula (I), X represents oxygen or sulfur; R1 represents lower alkyl, cycloalkyl(lower alkyl) or cycloalkyl; R2 represents hydrogen, halogeno, lower alkyl, halo(lower alkyl), hydroxy(lower alkyl), mercapto(lower alkyl), (lower alkoxy)(lower alkyl), (lower alkylthio)(lower alkyl), (lower alkanoyloxy)(lower alkyl), (lower alkanoylthio)(lower alkyl), (lower alkanoyl)(lower alkyl), hydroxyimino(lower alkyl), (lower alkoxyimino)(lower alkyl), cycloalkyl, aryl or lower alkanoyl; R3 represents hydrogen, halogeno or lower alkyl; R4 represents hydrogen, or lower alkyl; R5 represents cycloalkyl optionally substituted by the same group as R6; naphthyl optionally substituted by the same group as R6 a 5- or 6-membered monocyclic heterocycle optionally substituted by the same group as R6, optionally fused with a benzene ring and having one to four heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur atoms; or a group of formula (a); and R6 represents halogeno, lower alkyl, halo(lower alkyl), hydroxy, lower alkoxy, cyano or nitro.

  由通式(I)代表的化合物或其药学上可接受的盐，具有抑制IV型磷酸二酯酶活性的作用，可用作药物，特别是IV型磷酸二酯酶抑制剂或预防和治疗与sthenic IV型磷酸二酯酶活性有关的疾病，特别是呼吸系统疾病，如支气管哮喘。在所述式（I）中，X 代表氧或硫；R1 代表低级烷基、环烷基（低级烷基）或环烷基；R2 代表氢、卤素、低级烷基、卤代（低级烷基）、羟基（低级烷基）、巯基（低级烷基）、（低级烷氧基）（低级烷基）、（低级烷硫基）（低级烷基）、（低级烷酰氧基）（低级烷基）、（低级烷酰硫基）（低级烷基）、（低级烷酰基）（低级烷基）、羟基亚氨基（低级烷基）、（低级烷氧基亚氨基）（低级烷基）、环烷基、芳基或低级烷酰基；R3 代表氢、卤素或低级烷基；R4 代表氢或低级烷基；R5 代表环烷基，可任选被与 R6 相同的基团取代；萘基，可任选被与 R6 相同的基团取代；5 或 6 元单环杂环，可任选被与 R6 相同的基团取代，可任选与苯环融合，并具有一至四个杂原子，这些杂原子选自由氮、氧和硫原子组成的组；或式 (a) 的基团；以及 R6 代表卤素、低级烷基、卤代（低级烷基）、羟基、低级烷氧基、氰基或硝基。
• Combination of a pde iv inhibitor and a tnf-alpha antagonist
  申请人：Warner M James

  公开号：US20060083714A1

  公开（公告）日：2006-04-20

  The subject invention relates to therapeutic combinations and methods for the treatment of inflammatory conditions and diseases. Particularly the present invention relates to treatments and methods for PDE IV-related conditions and for TNF-alpha-related conditions using a combination of a PDE IV inhibitor and a TNF-alpha antagonist.

  本发明涉及治疗炎症和疾病的治疗组合和方法。特别是本发明涉及使用 PDE IV 抑制剂和 TNF-α 拮抗剂组合治疗 PDE IV 相关疾病和 TNF-α 相关疾病的治疗方法。
• METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY
  申请人：Whalen Anne

  公开号：US20110224128A1

  公开（公告）日：2011-09-15

  The invention features methods, compositions, and kits useful for the treatment of muscular dystrophy, e.g., Duchenne muscular dystrophy, in a patient.
• US6136810A
  申请人：——

  公开号：US6136810A

  公开（公告）日：2000-10-24
• [EN] METHODS AND COMPOSITIONS FOR TREATMENT NF-?B-MEDIATED AND a7 INTEGRIN-SUPPRESSED DISEASES<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR LE TRAITEMENT DE MALADIES À MÉDIATION PAR NF-?? ET SUPPRIMÉES PAR L'INTÉGRINE ?7
  申请人：DMD THERAPIES LLC

  公开号：WO2011146819A2

  公开（公告）日：2011-11-24

  The invention features compositions, methods, and kits useful for the treatment of diseases mediated by NF-κΒ and diseases suppressed by α7 integrin.